Kamada Ltd.
KMDADrugs in Pipeline
11
Phase 3 Programs
5
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
Active rabies vaccine (US-FDA approved)
Rabies
KamRAB - HRIG
Rabies
Alpha 1-Antitrypsin
Alpha 1-Antitrypsin Deficiency
Kamada AAT for inhalation
Emphysema
Kamada-API
Alpha 1-Antitrypsin Deficiency
Alpha-1 Antitrypsin 40mg (AAT, Glassia®)
Type 1 Diabetes Mellitus
Aerosolized, human, plasma-derived Alpha-1 Antitrypsin
Cystic Fibrosis
GLASSIA® and Institution standard of care (SOC)
Transplantation, Lung Rejection
Alpha-1 Antitrypsin
New Onset Type-1 Diabetes
Kamada-AAT for Inhalation, 80mg
Alpha-1 Antitrypsin Deficiency
Kamada Anti-SARS-CoV-2
Covid19
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Active rabies vaccine (US-FDA approved) | Phase 3 | Rabies | - | - |
KamRAB - HRIG | Phase 3 | Rabies | - | - |
Alpha 1-Antitrypsin | Phase 3 | Alpha 1-Antitrypsin Deficiency | - | - |
Kamada AAT for inhalation | Phase 3 | Emphysema | - | - |
Kamada-API | Phase 3 | Alpha 1-Antitrypsin Deficiency | - | - |
Alpha-1 Antitrypsin 40mg (AAT, Glassia®) | Phase 2 | Type 1 Diabetes Mellitus | - | - |
Aerosolized, human, plasma-derived Alpha-1 Antitrypsin | Phase 2 | Cystic Fibrosis | - | - |
GLASSIA® and Institution standard of care (SOC) | Phase 2 | Transplantation, Lung Rejection | - | - |
Alpha-1 Antitrypsin | Phase 2 | New Onset Type-1 Diabetes | - | - |
Kamada-AAT for Inhalation, 80mg | Phase 2 | Alpha-1 Antitrypsin Deficiency | - | - |
Kamada Anti-SARS-CoV-2 | Phase 2 | Covid19 | - | - |